Epidemiology and Resistance Mechanisms of Group B Streptococci in Late-pregnant Maternal Birth Canal

KUANG Ling-han, MU Li-yuan, SU Min. et al

Abstract

To study the antibiotic-resistant rate of group B Streptococci (GBS) in obstetric canal of late-pregnant women, evaluate the antibiotic-resistant status and finally to support the GBS prevention and curing by proper antibiotics. Methods 31 pregnant women between 35 to 37 gestational weeks were included, for whom the antibiotic sensitivity as well as the drug (erythromycin and clindamycin) resistance genes of GBS in obstetric canal was analyzed. Results 12 (38.7%) strains of GBS were resistant to clindamycin, while 21 (67.7%) to erythromycin, within which 12 strains were intrinsic phenotype ——cMLS type-clindamycin resistance, other 9 were active efflux phenotype ——MS type-clindamycin sensitive and all of which were confirmed by Double disk diffusion method. Eleven strains were mef (A) positive, and 12 strains were erm (B) positive, in which 3 with erm (C). Conclusions In our research the GBS strains show a high erythromycin and clindamycin resistance rate. The resistance of our GBS strains are mainly caused by the ribosomal target changes induced by erm (B) and the increased efflux of clindamycin induced by mef (A).

 

Keywords: Streptococcus agalactiae, Pregnant woman, Colonization, Resistance, Resistance mechanism 

 

 

 

Full Text:

PDF


References


Schrag S, Gorwitz R, Fultz-Butts K, et al. Prevention of perinatal group В streptococcal disease. Revised guidelines from CDC. MMWR Recomm Rep,2010;51(RR-ll): 1-22.

Castor ML, Whitney CG, Como-Sabetti K, et at. Antibiotic resistance patterns in invasive group В streptococcal isolates. Infect Dis Obstet Gynecol, 2008; 2008: 727505. doi; 10.1155/ 2008/727505.

Valkenburg-van den Berg AW, Houtman-Roelofsen RL, Oostvogel PM, et al. Timing of group В streptococcus screening in pregnancy: a systematic review. Gynecol Obstet Invest,2010;69(3):174-183.

Phares CR, Lynfield R, Farley MM. et al. Epidemiology of invasive group В streptococcal disease in the United States, 1999-2005. J AM A, 2008; 299 ( 17); 2056-2065.

RANZCOG. Maternal Group В Streptococcus in Pregnancy: screening and management, RANZCOG statement C-Obs 19. Melbourne; Royal Australian and New Zealand College of Obstetricians and Gynaecologists, 2012:1-19.

Leclercq R. Mechanisms of resistance to macrolides and lincosamides; nature of the resistance elements and their clinical implications. Clin Infect Dis,2002;34(4):482-492. Suzanne MG, Erin C.Lisa M ,et al. Antimicrobial resistance in group В streptococcus: the Australian experience. J Med Microbiol,2011; 60( Pt 2): 230-235.

Perez-Trallero E. Montes M. Orden B, et al. Phenotypic and genotypic characterization of St reptococcu spyogenes isolates displaying the MLSB phenotype of macrolide resistance in Spain. 1999 to 2005 . Antimicrob Agents Chemother.2007 ; 51 (4):1228-1233.

Klaassen CHW. Mouton JW. Molecular detection of the macrolide efflux gene; to discriminate or not to discriminate between mef ( A ) and mef ( E ). Antimicrob Agents Chemother, 2005; 49(4): 1271-1278.

Uh Y, Hwang GY, Jang IH, et al. Macrolide resistance trends in beta-hemolytic streptococci in a tertiary Korean hospital. Yonsei Me J .2007;48(5):773-778.

Janapatla RP. Ho YR. Yan JJ, et al. The prevalence of erythromycin resistance in group В streptococcal isolates at a University Hospital in Taiwan. Microb Drug Resist, 2008; 14 (4):293-297.

Decoster L. Frans J, Blanckaert H. et al. Antimicrobial susceptibility of group В streptococci collected in two Belgian hospitals. Acta Clin Belg,2005;60(4): 180-184.

Gherardi G, Imperi M. Baldassarri L. et al. Molecular epidemiology and distribution of serotypes, surface proteins, and antibiotic resistance among group В streptococci in Italy. J Clin Microbiol. 2007;45(9): 2909-2916.

Biedenbach DJ, Stephen JM, Jones RN. Antimicrobial susceptibility profile among beta-haemolytic Streptococcus spp. Collected in the SENTRY Antimicrobial Surveillance Program—North America, 2001. Diagn Microbiol Infect Dis, 2003;4 6(4):291-294.

de Azavedo JC, McGavin M. Duncan C, et al. Prevalence and mechanisms of macrolide resistance in invasive and noninvasive group В streptococcus isolates from Ontario. Canada. Antimicrob Agents Chemother.2001;45(12);3504-3508.

Cai Y. Kong F. Gilbert GL. Three new macrolide efflux (.mef) gene 4'ariants in Streptococcus agalactiae. J Clin Microbiol, 2007;45(8);2754-2755.

Hsueh PR. Teng LJ, Lee LN, et al. High incidence of erythromycin resistance among clinical isolates of Streptococcus agalactiae in Taiwan. Antimicrob Agents Chemother,2001;45 (11):3205-3208.

Morikawa Y. Kitazato M, Katsukawa С, et al. Prevalence of cefotaxime resistance in group В streptococcus isolates from Osaka, Japan. J Infect Chemother,2003;9(2); 131-133.

Kimura K, Suzuki S, Wachino J, et al. First molecular characterization of group В streptococci with reduced penicillin susceptibility. Antimicrob Agents Chemother, 2008; 52 ( 8 ): 2890-2897.

Nagano N, Nagano Y, Kimura K, et al. Genetic heterogeneity in pbp genes among clinically isolated group В streptococci with reduced penicillin susceptibility. Antimicrob Agents Chemother, 2008; 52( 12);4258-4267.


Refbacks

  • There are currently no refbacks.